ERBB2 and neoplasm: De novo engineered T cells are currently under clinical study in GBM, including the targeting of the tumor-associated antigens IL13Rα2, HER2, and EGFRvIII (NCT04003649, NCT03696030, and NCT02664363) [18,21,22].